PSA screening-for whom and when?
- Author:
Peter ALBERS
1
Author Information
- Publication Type:Journal Article
- From: Asian Journal of Andrology 2019;21(1):3-5
- CountryChina
- Language:Chinese
- Abstract: Reasons for and against screening of prostate cancer have been discussed widely over the last decade. In 2014, the European Randomized Trial for Screening of Prostate Cancer (ERSPC) has reported a relative reduction of the cancer-specific survival of 27% in participants who definitely followed the screening protocol. This relative advantage has proven to be stable from year 7 to year 13 after the beginning of screening. Still, the disadvantages of overdiagnosis and overtreatment are the downsides of a population-based screening approach. But given the overall advantage of screening, a risk-Adapted prostate-specific antigen (PSA) screening using a baseline PSA value at ages 45-50 may significantly reduce the number needed to diagnose maintaining the benefits of screening. PROBASE is a randomized risk-Adapted screening trial currently ongoing in Germany to answer this important question.
